


# CURRENT ACTIVITIES BY PHARMA

## ADDRESSING THE FIGHT WITH THE COVID-19 DISEASE

March 23, 2020 | UPharma Consulting | [upharma-c.com/en/](http://upharma-c.com/en/)



### COVID-19 DESCRIPTION

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China. @CDC

Organization	Type	Target	Phase	Current status & plans	Timeline	Source
GILEAD	Treatment	Remdesivir	III	Remdesivir is now being tested in five Covid-19 clinical trials that have been set up at breakneck speed.	CT results are expected in April 2020	<a href="#">link</a>
SANOFI	Treatment + Vaccine	Plaquenil®	Preclinical	Conduct additional CTs and supply millions of doses of an existing anti-malaria product	N.a.	<a href="#">link</a>
PFIZER BIONTECH	Treatment + Vaccine	New mRNA vaccine	Preclinical	Co-development of a new product clinical testing in humans. Germany's BioNTech uses strands of mRNA to spur the production of protective antibodies.	CTs are planned to be started in April 2020	<a href="#">link</a>
JOHNSON & JOHNSON	Vaccine	Covid-19 vaccine	Preclinical	J&J is using the same vaccine platform it used to develop its Ebola vaccine	R&D – in Jan 2020 & CT to be started by the end of Nov 2020	<a href="#">link</a>
ABBVIE	Treatment	lopinavir/ritonavir combination	III	The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.	N.a.	<a href="#">link</a>
VACCITECH	Vaccine	lopinavir/ritonavir combination	IIb	A platform to new next-generation sequencing workflows focused in microbiology and infectious disease, including for the novel coronavirus.	Started in March 2020	<a href="#">link</a>
REGENERON	Treatment	Monoclonal antibody therapy	Preclinical	To select the top 2 antibodies for a cocktail therapy, which can either be administered to at-risk people before exposure as a vaccine or as treatment for those already infected.	Potential to enter human CT by early summer 2020	<a href="#">link</a>
ASCLEPTIS	Treatment	Combination of two antivirals	I	The Chinese manufacturer is testing a combination of antivirals, one approved for HIV and one approved for hepatitis C, that might treat coronavirus infection	N.a.	<a href="#">link</a>
TAKEDA	Treatment	Polyclonal antibody therapy	Preclinical	Collaboration with several health and regulatory agencies and health care partners across the globe on its TAK-888. The company is trying to access to source plasma from people who have successfully recovered from COVID-19	Started in March 2020	<a href="#">link</a>
HOTH THERAPEUTICS	Vaccine	Self-assembling vaccine (SAV)	Preclinical	An agreement with Voltron Therapeutics was signed, to form a "HaloVax" JV, to commence preclinical studies for the development of vaccine prospects against COVID-19 based upon VaxCelerate, a self-assembling vaccine (SAV) platform.	End of March 2020	<a href="#">link</a>
MODERNA	Vaccine	mRNA-1273	I	A vaccine candidate was identified by Moderna just 42 days after the novel coronavirus was sequenced. The clinical trial started recruiting healthy participants in the first week of March.	CT results are expected in summer 2020	<a href="#">link</a>
CAN-SINO-BIO	Vaccine	Covid-19 vaccine	I	CanSino's approach involves taking a snippet of coronavirus' genetic code and entwining it with a harmless virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies.	CT to be started in March 2020	<a href="#">link</a>
ARCTURUS THERAPEUTICS	Vaccine	Covid-19 vaccine	Preclinical	The company in partnership with Duke University plans to take an RNA virus that has been edited to encode for proteins that will protect against infection and load it into a liquid nanoparticle.	CT to be started in March-April 2020	<a href="#">link</a>
ABCELLERA LILLY	Treatment	Antibody drug	Preclinical	Eli Lilly has partnered with a Canadian firm called AbCellera to develop antibody treatments for coronavirus infection. Using a blood sample from a coronavirus survivor, AbCellera identified more than 500 antibodies that might protect against the virus.	CTs in humans to be started in the next four months of 2020	<a href="#">link</a>
GSK GLAXOSMITHKLINE	Vaccine	Covid-19 vaccine	Preclinical	GSK is lending its technology to a Chinese – Clover Biopharmaceuticals – at work on a coronavirus vaccine. Clover's approach involves injecting proteins that spur an immune response, thereby priming the body to resist infection.	N.a.	<a href="#">link</a>
INOVIO	Vaccine	Covid-19 vaccine	Preclinical	Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology.	CTs are planned to be started in April 2020	<a href="#">link</a>